Searchable abstracts of presentations at key conferences in endocrinology
ISSN 1470-3947 (print)
| ISSN 1479-6848 (online)
Endocrine Abstracts
Menu
Search
Issues/Conferences
Cite
About
Our Services
Policies
Contact
Disclaimer
Search
Issues/Conferences
Cite
About
Our Services
Policies
Contact
Disclaimer
Previous issue
|
Volume 89
|
NANETS2022
|
Next issue
NANETS 2022
All volumes
0104 SFEIES24
0103 BSPED2024
0102 EYES2024
0101 ETA2024
0100 SFEEU2024
0099 ECE2024
0098 NANETS2023
0097 BES2023
0096 UKINETS2023
0095 BSPED2023
0094 SFEBES2023
0093 EYES2023
0092 ETA2023
0091 SFEEU2023
0090 ECE2023
0089 NANETS2022
0088 BES2022
0087 UKINETS2022
0086 SFEBES2022
0085 BSPED2022
0084 ETA2022
0083 EYES2022
0082 SFEEU2022
0081 ECE2022
0080 UKINETS2021
0079 BES2021
0078 BSPED2021
0077 SFEBES2021
0076 CHD2021
0075 EYES2021
0074 SFENCC2021
0073 ECE2021
0072 UKINETS2020
0071 BES2020
0070 ECE2020
0069 SFENCC2020
0068 UKINETS2019
0067 EYES2019
0066 BSPED2019
0065 SFEBES2019
0064 BES2019
0063 ECE2019
0062 EU2019
0061 OU2019
0060 UKINETS2018
0059 SFEBES2018
0058 BSPED2018
0057 BES2018
0056 ECE2018
0055 SFEEU2018
0054 NuclearReceptors2018
0053 OU2018
0052 UKINETS2017
0051 BSPED2017
0050 SFEBES2017
0049 ECE2017
0048 SFEEU2017
0047 Theranostics2016
0046 UKINETS2016
0045 BSPED2016
0044 SFEBES2016
0043 WCTD2016
0042 Androgens2016
0041 ECE2016
0040 ESEBEC2016
0039 BSPED2015
0038 SFEBES2015
0037 ECE2015
0036 BSPED2014
0035 ECE2014
0034 SFEBES2014
0033 BSPED2013
0032 ECE2013
0031 SFEBES2013
0030 BSPED2012
0029 ICEECE2012
0028 SFEBES2012
0027 BSPED2011
0026 ECE2011
0025 SFEBES2011
0024 BSPED2010
0023 BSPED2009
0022 ECE2010
0021 SFEBES2009
0020 ECE2009
0019 SFEBES2009
0018 MES2008
0017 BSPED2008
0016 ECE2008
0015 SFEBES2008
0014 ECE2007
0013 SFEBES2007
0012 SFE2006
0011 ECE2006
0010 SFE2005
0009 BES2005
0008 SFE2004
0007 BES2004
0006 SFE2003
0005 BES2003
0004 SFE2002
0003 BES2002
0002 SFE2001
Summary
Abstracts
Abstract Book
Volume Editors
Contents
15th Annual Multidisciplinary NET Medical Symposium NANETS 2022
Basic Science
Single-Cell ATAC and Single-Nucleus RNA Sequencing Uncovers Cellular Heterogeneity Within Pancreatic Neuroendocrine Tumors
ea0089b1
Multiple Layers of Epigenetic Regulation Cooperate to Silence Expression of Somatostatin Receptor Type 2 in Pancreatic Neuroendocrine Tumors
ea0089b2
Development of a Novel Anti-SSTR Bispecific T-Cell Engager (BiTE)-like Molecule for the Treatment of Neuroendocrine Tumors
ea0089b3
Simultaneous Inhibition of DNA Methylation and Histone De-acetylation for Enhanced SSTR2 Expression In Vitro
ea0089b4
Oncolytic Seneca Valley Virus (SVV-001) Overcomes Checkpoint Inhibitor Resistance and Demonstrates a Systemic Anti-tumor Response in a Syngeneic Tumor Model
ea0089b5
Detecting Cell Surface Expression of Calreticulin in Pancreatic Neuroendocrine Tumors Using a Novel [68Ga]-Radiolabeled Peptide
ea0089b6
All-Trans Retinoic Acid Radiosensitizes Neuroendocrine Tumor Cells via Peptidyl-Prolyl Cis-Trans Isomerase 1 Inhibition
ea0089b7
CDK4/6-MEK Targeted Therapy Causes Regression and Reduced Metastatic Colonization of Pancreatic Neuroendocrine Tumors
ea0089b8
Deletion of Notch1 Signaling in Pancreatic Neuroendocrine Tumors Reduces Metastatic Properties
ea0089b9
Inhibition of Estrogen Receptor Alpha Radiosensitizes Neuroendocrine Tumors
ea0089b10
Patient-Derived Organoids and Their Potential for Precision Medicine in Neuroendocrine Tumors
ea0089b11
Transcriptomic Influences of Racial Disparities in Black Patients with Pancreatic Neuroendocrine Tumors
ea0089b12
Optical Genome Mapping: a Novel Approach to Identifying Structural Variants in Metastatic Neuroendocrine Tumors
ea0089b13
Pancreatic Mixed Acinar-Neuroendocrine Carcinoma: a Single Institutional Genomic Characterization Report
ea0089b14
Targeting the TCA Cycle with Histone Deacetylase and Nicotinamide Phosphoribosyltransferase Inhibitors Uncovers a Critical Role for YAP1 in Neuroendocrine Cells
ea0089b15
[212Pb]PSC-PEG2-TOC Therapy for NET Leads to Complete Responses in Mice Bearing SSTR2 Positive Tumors - Comparison to [177Lu]DOTATATE in a Preclinical Model
ea0089b16
Clinical – Chemo/SSA/Biologics
Progression-Free Survival in Patients with Bronchopulmonary Neuroendocrine Tumors Treated with Lanreotide or Placebo: Adjustment for Crossover Effects in Placebo Arm
ea0089c1
Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Neoplasms
ea0089c2
Real World Analysis of Long-Acting Somatostatin Analog (LA-SSA) Treatment and Dose Escalation Among Patients with Neuroendocrine Tumors (NET)
ea0089c3
Cisplatin vs Carboplatin in Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas (PD NEC)
ea0089c4
c-MET Expression in MEN1-associated Neuroendocrine Tumors
ea0089c5
An Open-Label, Phase 1b/2 study of Surufatinib in Combination with Tislelizumab in Patients with Advanced Neuroendocrine Tumors
ea0089c6
Risk of Myelodysplastic Syndrome/Acute Leukemia with Sequential Capecitabine/Temozolomide and 177Lu-Dotatate
ea0089c7
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-Differentiated Neuroendocrine Tumors
ea0089c8
Correlation of MEN1 and DAXX Mutational Status with Response to Capecitabine and Temozolomide (CAPTEM) in Pancreatic Neuroendocrine Tumors
ea0089c9
ACTH-secreting Pancreatic Neuroendocrine Neoplasms: A Case-Series
ea0089c10
Results from the Phase 1, Randomized, Open-Label, Cross-Over Study to Evaluate Pharmacokinetics of Three Escalating Doses of Oral Octreotide Capsules
ea0089c11
Financial Toxicity and Supportive Care in Neuroendocrine Tumor: A Biobank Study
ea0089c12
Serum Serotonin Compared to Plasma 5-HIAA and Chromogranin A as Biomarkers of Response to Hepatic Artery Bland Embolization
ea0089c13
Clinical – Nuclear Medicine/Interventional Radiology/Imaging
Cardiac Neuroendocrine Tumor Metastases on 68Ga-DOTATATE PET/CT
ea0089c14
Effectiveness and Safety of Re-Treatment With 177Lu-DOTATATE in Patients With Progressive NETs in the US: a Retrospective Real-World Study
ea0089c15
Clinical Utility of Somatostatin Receptor Positron Emission Tomography Imaging Biomarkers for Characterization of Meningioma Among Incidental Central Nervous System Lesions
ea0089c16
Integration of Radioembolization with CapTem for Liver-Dominant G2 NETs: Long-Term Outcomes
ea0089c17
Radiosensitization for TARE: Does Duration of Chemotherapy Affect PFS?List of participants and their roles in the submission
ea0089c18
Transformation of G1-G2 Neuroendocrine Tumors (NETs) to Neuroendocrine Carcinomas (NECs) Following Peptide Receptor Radionuclide Therapy (PRRT): a Case Series
ea0089c19
Quality of Life Assessments for Advanced Pheochromocytoma and Paraganglioma Patients that Received High-Specific-Activity I-131 MIBG: Results from a Pivotal Phase 2 Clinical Trial
ea0089c20
Characterizing Bone Metastases in Patients with Well-Differentiated Neuroendocrine Neoplasms Utilizing Ga68-DOTATATE PET
ea0089c21
The Role of 68Ga-DOTATATE PET/CT in the Management of Gastrointestinal and Pancreatic Neuroendocrine Tumors
ea0089c22
Somatostatin receptor expression in lung neuroendocrine tumors: an analysis of Dotatate PET scans
ea0089c23
MIBG and DOTATATE Therapy for Pheochromocytoma and Paraganglioma: A Single Institution Experience
ea0089c24
Evaluation of 68Ga-DOTATATE PET After Two Cycles of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
ea0089c25
Pre-therapy Functional Imaging with MIBG and DOTATATE to Guide Radiopharmaceutical Therapy for Pheochromocytoma and Paraganglioma: A Single Institution Experience
ea0089c26
Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT, CT, and MRI Spine in the Detection of Spinal Bone Metastases in Metastatic Pheochromocytoma/Paraganglioma
ea0089c27
Diagnostic Performance of PET or PET/CT Utilizing 18F-DOPA, 68Ga-DOTATATE, 18F-FDG, 18F-FDA, and CT and MRI in the Detection of MEN2A-related-pheochromocytoma
ea0089c28
Diagnostic Performance of PET or PET/CT Utilizing 18F-DOPA, 68Ga-DOTATATE, 18F-FDG, 18F-FDA, and CT and MRI the Detection of VHL-related Pheochromocytoma
ea0089c29
Clinical – Surgery/Applied Pathology
Liver-Directed Therapy of Neuroendocrine Liver Metastases
ea0089c30
Goblet Cell Adenocarcinoma (GCA) of the Appendix: Interrogating Proteomics to Identify Potential Actionable Targets
ea0089c31
Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
ea0089c32
High-Grade Pancreatic Neuroendocrine Neoplasms: Interobserver Diagnostic Accuracy and Relationship with Clinicopathological and Molecular Characteristics
ea0089c33
Grade Creep and the Importance of Tissue Sampling: Changes in Ki-67 and Grade in Serial Neuroendocrine Tumor Samples
ea0089c34
Liver Directed Therapy is Associated with Improved Survival in Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms with Concurrent Bone Metastasis
ea0089c35
Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?
ea0089c37
Increased Incidence, Prevalence, and Surgical Management of Enteropancreatic Neuroendocrine Tumors Is Associated with Improvements in Survival - A Contemporary Analysis
ea0089c38
Have We Accounted for Asians? A Critical Analysis of Racial Cancer Disparity Amongst Asian Pancreatic Neuroendocrine Tumor Patients
ea0089c39
TP53 Mutation Portends a Worse Overall Survival in Patients with Advanced Grade 3 Well-Differentiated Neuroendocrine Tumors
ea0089c40
SSTR-2 Expression in Solid Tumors: An Immunohistochemistry Analysis
ea0089c41
Small Intestinal NET Recurrence - When Why and How?
ea0089c42
Post-Operative Biochemical Surveillance Thresholds Can be Used to Monitor for Sympathetic Pheochromocytoma/Paraganglioma Recurrence and Metastasis
ea0089c43
Population Science
Cervical Neuroendocrine Carcinomas: A Population-Based Analysis of Clinicopathologic Characteristics and Survival Outcomes in Comparison with Conventional Cervical Malignancies
ea0089p1
Factors Impacting Survival Outcomes of Islet Cell Carcinoma
ea0089p2
Socioeconomic Factors, Treatment Modality, and Survival in Islet Cell Carcinoma: A National Cancer Database Analysis
ea0089p3
Carcinoid Heart Disease in Patients Diagnosed with Small Bowel and Lung Neuroendocrine Tumors
ea0089p4
Comparison of Demographics and Overall Survival (OS) Among Patients with Young-Onset(YO) and Late-Onset(LO) GI Neuroendocrine Tumors/Carcinomas (NETs/NECs) in the United States
ea0089p5
Evaluating the Impact of Education on Clinician Integration of Guidelines, Real-World Data, and Patient Perspectives on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
ea0089p6
Feasibility of e-NET: A Web-Based Health Platform to Investigate Quality of Life in Patients with Neuroendocrine Tumors
ea0089p7
Multivisceral Surgical Resection of Locally Advanced Pancreatic Neuroendocrine Tumor is Associated with a Survival Benefit
ea0089p8
Lifestyle and Neuro-endocrine Tumor (NET) Development Within the European Prospective Investigation into Cancer and Nutrition (EPIC) Cohort
ea0089p9
Environmental Pollution and GEP-NENS - Is There an Association?
ea0089p10
Other
Efficacy and Toxicity of Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Tyrosine Kinase Inhibitors (TKIs) in Neuroendocrine Tumors (NETs) - A Systematic Review and Meta-Analysis
ea0089o1
The Association Between Patient-Reported Symptom Burden and Urgent Healthcare Use in Patients Diagnosed with Neuroendocrine Tumors
ea0089o2
Germline Pathogenic Variants in Patients with High-Grade (G3) Metastatic Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)
ea0089o3
Immune Cell Molecular Pharmacodynamics of Lanreotide in Relation to Treatment Response
ea0089o4
Implementation of a Patient Advisor Program for Neuroendocrine Tumor Patients: Acceptability, Benefits and Potential Challenges
ea0089o5
Frequency of Pulmonary Carcinoid Tumor Research Presented at Major International Neuroendocrine and Lung Cancer Scientific Meetings
ea0089o6
Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumor Patients
ea0089o7
Variants of Uncertain Significance (VUS) are More Common in Non-Caucasian Patients with Neuroendocrine Neoplasms (NENs)
ea0089o8
Leveraging Transcriptomics to Grade Pancreatic Neuroendocrine Neoplasms(NENs) and Assess Molecular Alterations Associated with Somatostatin Receptor(SSTR) Subtype Expression
ea0089o9
Germline Cancer Testing in Unselected Patients with Neuroendocrine Neoplasms: A Multi-center Prospective Study
ea0089o10
Pheo Para Alliance Patient Centered Research on Challenges for Those with Pheochromocytoma and Paraganglioma
ea0089o11
An Appraisal of Findings from a Neuroendocrine Neoplasm (NEN) Tumor Board (TB): Is There Added Value or Is It Redundant?
ea0089o12
Trials In Progress
Phase Ia/Ib Study of BAY1895344 Plus Topoisomerase I Inhibitors with a Focus on Poorly Differentiated Neuroendocrine Carcinomas and Pancreatic Adenocarcinoma
ea0089t1
COMPOSE: Pivotal Phase III Trial for Well-Differentiated Aggressive Grade 2/3 Gastroenteropancreatic Neuroendocrine Tumors Comparing 177Lu-edotreotide with Best Standard of Care
ea0089t2
Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Carcinoid Syndrome
ea0089t3
Phase 1-2 Trial of Vesicular Stomatitis Virus Expressing Human Interferon-[beta] and NIS (VSV-IFN[beta]-NIS), with Pembrolizumab, in Patients with Neuroendocrine Carcinoma
ea0089t4
A Phase 2 Open-Label Study of Belzutifan (a HIF-2[alpha] Inhibitor) Monotherapy in Patients with Advanced/Metastatic Pheochromocytoma/Paraganglioma or Pancreatic Neuroendocrine Tumors
ea0089t5
ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA
ea0089t6
Methodology of the SORENTO Clinical Trial: Assessing Efficacy and Safety of High Exposure Octreotide Subcutaneous Depot in Patients with GEP-NET
ea0089t7
Phase II Trial Evaluating [177Lu]Lu-DOTA-TATE in Adolescents with Somatostatin Receptor (SSTR)-positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), Pheochromocytomas and Paragangliomas (PPGLs)
ea0089t8
PReCedeNT Trial: Phase III Randomised Controlled Trial of PRRT with Lutetium - 177 DOTATATE Plus Chemotherapy vs PRRT Alone in FDG-avid, Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors
ea0089t9
Pilot Study of TQ Formula in Combination with Nivolumab and Ipilimumab in Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECAs)
ea0089t10